

6. (amended) A specific binding member isolated from synthetic molecular repertoires which is specific for and binds directly to the ED-B oncofoetal domain of fibronectin (FN) produced by a process according to Claim[s] 1 [or 2].

9. (amended) A specific binding member according to [any one of] claim[s] 6 [to 8], which binds to all FNs containing ED-B after treatment of the FN with the protease thermolysin.

10. (amended) A specific binding member according to [any one of] claim[s] 6 [to 9], which binds to all recombinant FNs containing type III homology repeats which include the ED-B domain.

11. (amended) A specific binding member according to [any one of] claim[s] 6 [to 10] whose binding to B-FN is inhibited by the ED-B domain.

12. (amended) A specific binding member according to [any one of the preceding] claim[s] 6, which binds to B-FN from human, mouse, rat, chicken and any other species in which the ED-B domain is conserved.

13. (amended) A specific binding member according to [any one of the preceding] claim[s] 6 which binds to B-FN without treatment of the FN with N-glycanase.

14. (amended) A specific binding member according to [any one of the preceding] claim[s] 6 having a variable heavy (VH) chain region of the sequence derived from human germline DP47 (codon 1 Glu - codon 98 Arg inclusive in Figure 1) and the CDR3 sequence Ser Leu Pro Lys.

15. (amended) A specific binding member according to [any one of] claim[s] 6 [to 13] having a variable heavy (VH) chain region of the sequence derived from human germline DP47 (codon 1 Glu - codon 98 Arg inclusive in Figure 1) and the CDR3 sequence Gly Val Gly Ala Phe Arg Pro Tyr Arg Lys His Glu.

16. (amended) A specific binding member according to [any one of claim[s] 6 [to 13] having a variable light (VL) chain region of the sequence derived from human germline DPL16 (codon 1 Ser - codon 90 Ser inclusive in Figure 1) and the remainder of the CDR3 sequence as Pro Val Val Leu Asn Gly Val Val.

17. (amended) A specific binding member according to [any one of] claim[s] 6 [to 13] having a variable light (VL) chain region of the sequence derived from human germline DPL16 (codon 1 Ser - codon 90 Ser inclusive in Figure 1) and the remainder of the CDR3 sequence as Pro Phe Glu His Asn Leu Val Val.

18. (amended) A specific binding member according to [any one of] claim[s] 6 [to 13] having a variable heavy (VH) chain region of the sequence derived from human germline DP47 (codon 1 Glu - codon 98 Arg inclusive in Figure 1) and the CDR3 sequence.

19. (amended) A specific binding member according to [any one of the preceding] claim[s] 6 which, when measured as a purified monomer, has a dissociation constant (Kd) of 6×10^{-8} M or less for ED-B FN.

20. (amended) A specific binding member according to [any one of the preceding] claim[s] 6, wherein said binding member comprises an scFv molecule.

21. (amended) A specific binding member of [any of the preceding] claim[s] 6, wherein said binding member comprises a dimeric scFv molecule.

22. (amended) A specific binding member [of any one of the preceding] according to claim[s] 14, wherein said binding member is an antibody fragment [as defined in claims 14-18].

23. (amended) A pharmaceutical composition comprising a specific binding member according to [any one of the preceding] claims[s] 6 in an effective amount, in conjunction with a pharmaceutically acceptable excipient.